Tissue factor and tissue factor pathway inhibitor in patients with nephrotic syndrome;Czynnik tkankowy i inhibitor zewnatrzpochodnej drogi krzepniecia w zespole nerczycowym

Polskie Archiwum Medycyny Wewnetrznej

Volumn 101, Issue 4, 1999, Pages 301-305

  Małyszko, Jacek S ^a   Małyszko, Jolanta ^a   Myśliwiec, Michał ^a  

^a Wewnetrznych AM w Bia ymstoku

Author keywords

Nephrotic syndrome; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VITRONECTIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEPHROTIC SYNDROME;

ADULT; AGED; BIOLOGICAL MARKERS; FACTOR VII; FACTOR X; FACTOR XA; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; THROMBOMODULIN; THROMBOPLASTIN; VITRONECTIN;

EID: 0033107709     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vaziri N.D., Bremson H.E., Ness R.: Changes of coagulation factors IX, VIII, VII, X and V in nephrotic syndrome. Am J. Med., 1980, 280, 168.
2. Thompson C., Forbes C.D., Prentice C.R.M., Kennedy A.C.: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Quart. J. Med., 1974, 43, 339.
3. Machleid C., Mettang T., Starz E., Weber J., Risler T., Kuhlmann K.: Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int., 1989, 36, 1119.
4. Robert A., Olmer M., Sampol J., Gugliotta J.E., Casanova P.: Clinical correlation between hypercoagulability and thromboembolic phenomena. Kidney Int., 1987, 31, 830.
5. Rydzewski A., Myśliwiec M., Soszka J.: Concentration of three thrombin in the nephrotic syndrome in adults. Nephron, 1986, 42, 200.
6. Llach F.: Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int., 1985, 28, 429.
7. Kanfer A., Kleinknecht D., Broyer M., Josso F.: Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb. Diathes. Haemorrh., 1970, 24, 562.
8. Edward N., Young D.P., McLeod M.: Fibrinolytic activity in plasma and urine in chronic renal diseases. J. Clin. Pathol., 1961, 17, 375.
9. Andreenko C.V., Podoroloskaya L.V., Polentseva L.R.: The role of fibrinolysis in pathogenesis of chronic glomerulonephritis. Thromb. Haemostas., 1979, 42, 66.
10. Grundy S.M.: Management of hyperlipidemia of kidney disease. Kidney Int. 1990, 37, 847.
11. Morrisey J.H., Neuenschwander P.F., Huang Qmc Callum C.D., Su B, Johnson A.E.: Factor VIIa-tissue factor: functional importance of protein-membrane interactions. Thromb. Haemostas., 1997, 78, 112.
12. Broze G.J., Jr: Tissue factor pathway inhibitor. Thromb. Haemost., 1995, 74, 90.
13. Bajaj M.S., Bajaj S.P.: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost., 1997, 78, 471.
14. Kario K., Matsuo T., Yamada T., Matsuo M.: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb. Haemost., 1994, 71, 272.
15. Koyama T., Nishida K., Ohdama S., i wsp.: Determination of plasma tissue factor antigen and clinical significance. Brit J. Haematol, 1994, 87, 343.
16. Fukuda C., Iijima K., Nakamura K.: Measuring tissue factor (factor III) activity in plasma. Clin. Chem., 1989, 35, 1897.
17. Ogawa T., Ito T., Yorioka N., Yamakido S., Nakamura M.: Ultrastructural localisation of tissue factor in human renal tissues. J. Am. Soc. Nephrol., 1997, 8, 481.
18. Schena F.P., Grandaliano G., Gesualto L., Mouno R., Ranieri E., Andriola S.: The coagulation cascade activation in the pathogenesis of human crescentic glomerulonephritis (CGN) J. Am. Soc. Nephrol., 1997, 8, 507.
19. Erlich J.H., Apostolopoulos J., Wun T.C., Kretzmer K.K., Holdsworth S.R., Tipping P.G.: Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J. Clin. Invest., 1996, 98, 325.
20. Lwaleed B.A., Bass P.S., Chissholm M., Francis J.L.: Urinary tissue factor levels in glomerulonephritis: A potential marker of glomerular injury. J. Clin. Pathol. 1997, 50, 336.
21. Yamabe H., Osawa H., Inuma H., i wsp.: Tissue factor pathway inhibitor production by human mesangial cells in culture. Thromb. Haemost., 1996, 76, 215.
22. Cella G., Vertolli U., Naso A., i wsp.: Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb. Res., 1996, 81, 671.
23. Małyszko J., Małyszko J.S., Myśliwiec M.: TF and TFPI in CAPD and HD. Nephrol. Dial. Transplant., 1998, 13, 2424.
24. Malyszko J., Malyszko J., Pawlak D., i wsp.: A comprehensive study on platelet function, fibrino-lysis, peripheral serotonergic system and serum lipids in nephrotic syndrome. Pol. J. Pharmacol., 1996, 48, 191.
25. Kario K., Matsuo T., Matsuo M., i wsp.: Marked increase of activated factor VII in uremic patients. Thromb. Haemost., 1995, 73, 763.
26. Preissner K.T., Seiffert D.: Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb. Res., 89, 1, 1998.